We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

United Imaging Healthcare

United Imaging develops and produces a full portfolio of advanced medical products covering the entire process of ima... read more Featured Products: More products

Download Mobile App





Total-Body PET Imaging Can Assess Immunological Response to COVID-19 Infections

By HospiMedica International staff writers
Posted on 12 Aug 2022
Print article
Image: uEXPLORER is the world`s first total-body PET/CT scanner (Photo courtesy of United Imaging Healthcare)
Image: uEXPLORER is the world`s first total-body PET/CT scanner (Photo courtesy of United Imaging Healthcare)

Cytotoxic T cells are key players in the cell-mediated immune response against viral infections. However, 95% of T cells are in tissues rather than in the blood circulation and are therefore difficult to assess non-invasively. Now, high sensitivity PET imaging using a specific T cell radiotracer offers a new methodology to track tissue concentrations of T cells without invasive sampling.

UC Davis (Davis, CA, USA) which collaborated with United Imaging Healthcare Co., Ltd. (Shanghai, China) to develop the world's first total-body PET/CT scanner, 'uEXPLORER presented their research on COVID-19 at the 2022 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting. Guided by the uEXPLORER scanner along with a new labeled radiotracer with high affinity to T cells (89Zr-Crefmirlimab-Berdoxam), the scientists unveiled the first high-resolution PET image of total-body CD8+ T-cell distribution after COVID-19 infection. The image could shed light on the pathological mechanism and immune response to COVID-19 infection. The radiotracer used, 89Zr-Crefmirlimab-Berdoxam, is an investigational tracer provided for the study by ImaginAb who is currently in Phase IIb testing to determine predictive performance.

In the reported study, patients recovering from COVID-19 infection received a low injection dose (~0.5 mCi) of 89Zr-labeled radiotracer that targeted CD8+ T cells and underwent a uEXPLORER PET/CT scan at different time points. A control group was also studied. The total-body PET images revealed subtle differences between five recovering COVID-19 patients and three healthy volunteers. The exceptional image quality obtained using the uEXPLORER scanner confirmed CD8+ T cell deposition in the spleen, liver, bone marrow, lymph nodes, and tonsils, as well as differences in the clearance rate of the radiotracer from the blood. Imaging was accomplished with minimal radiation dose to the patients. This research paves the way for further exploration of the assessment of immune response to infectious diseases and cancer, the assessment of response to vaccines in human subjects, and the fundamental mechanisms of the immune system in general.

This disruptive technology co-developed by UC Davis and United Imaging pushes the boundaries of traditional PET scanners, with an effective sensitivity that is up to 68-fold greater than current commercial PET scanners. Combined with a 194 cm axial PET field of view, the uEXPLORER scanner can capture dynamic changes to radiotracer distribution across the entire human body with high temporal resolution, which is an essential attribute for this type of research.

“We have now contributed to several different disease areas based on the high sensitivity and total-body coverage of the uEXPLORER scanner,” said Simon R. Cherry, Ph.D., Distinguished Professor of Biomedical Engineering and Radiology at UC Davis “This research is another demonstration of how groundbreaking imaging technology, combined with highly specific radiotracers, can open new opportunities in studying the complex interactions within the whole body, both in health and in response to disease. We hope this research will contribute to a better understanding of the immunological response to COVID-19, and serve as an example for how the immune system can be interrogated at a systems level with total-body PET.”

Related Links:
UC Davis 
United Imaging Healthcare Co., Ltd. 

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Treatment Cart
Avalo Woodblend
New
Clinical Display
C14S

Print article

Channels

Critical Care

view channel
Image: Tissue plasminogen activator working to dissolving brain clot and improving blood flow to the part of the brain being deprived (Photo courtesy of American Heart Association)

Injecting Clot-Dissolving Drug After Removing Large Brain Artery Clot Improves Stroke Outcomes

Approximately 1 in 5 ischemic strokes, which are caused by a clot, occur due to a blockage in a large artery in the brain (large vessel occlusions). The standard treatment for this type of stroke is the... Read more

Surgical Techniques

view channel
Image: The KeyScope low-cost laparoscope enables high resolution surgical imaging (Photo courtesy of Barnes et al., doi 10.1117/1.BIOS.2.2.022302)

Low-Cost, Robust Laparoscope Addresses Cost, Power and Sterilization Challenges

Laparoscopic surgery, a minimally invasive technique, has revolutionized surgical practices in high-income countries. This method involves using a laparoscope to perform operations through small incisions,... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.